First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.  [electronic resource] 

 -  Prescrire international  Feb 2013 
 - 48-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1167-7422 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Androgen Antagonists--adverse effects<br/>Antineoplastic Agents, Hormonal--adverse effects<br/>Bone Neoplasms--metabolism<br/>Cyproterone--therapeutic use<br/>Estrogens--therapeutic use<br/>Flutamide--therapeutic use<br/>Goserelin--therapeutic use<br/>Humans<br/>Male<br/>Neoplasms, Hormone-Dependent--metabolism<br/>Orchiectomy--adverse effects<br/>Practice Guidelines as Topic<br/>Prostatic Neoplasms--metabolism<br/>Time Factors<br/>Treatment Outcome